Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis

Cancer Research

Volumn 62, Issue 15, 2002, Pages 4176-4179

  Miyajima, Akira ^a   Kosaka, Takeo ^a   Asano, Tomohiko ^a   Asano, Takako ^a   Seta, Kaori ^a   Kawai, Toshiaki ^a   Hayakawa, Masamichi ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFECT; KIDNEY CANCER; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; FEMALE; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0036681694     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Surgery of renal cell carcinoma
2. Renal-cell carcinoma
3. Metastatic renal-cell carcinoma: What causes occasional dramatic regressions?
4. The role of angiotensin receptors in cardiovascular diseases
5. Prevention of stroke and cancer: Could angiotensin II type 1 receptor antagonists do better than angiotensin II converting enzyme inhibitors?
6. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
7. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo
8. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane
9. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression
10. Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma
11. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist
12. Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: Heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma
13. Antibody to transforming growth factor-β ameliorates tubular apoptosis in unilateral ureteral obstruction
14. Angiotensin II receptors: Protein and gene structures, expression and potential pathological involvements
15. Recognition of tissue- and subtype-specific modulation of angiotensin II receptors using antibodies against AT1 and AT2 receptors
16. Angiotensin II in renal fibrosis: Should TGF-β rather than blood pressure be the therapeutic target?
17. Transforming growth factor-β: Vasculogenesis, angiogenesis, and vessel wall integrity
18. Candesartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker
19. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl] -1H-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats
20. Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist
21. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl] -1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl] -1H-benzimidazole-7-carboxylate (TCV-116)
22. Four-week oral toxicity study of TCV-116 in rats
23. Four-week oral toxicity study of TCV-116 in 10-month-old beagle dogs
24. Twenty-six-week oral toxicity study of TCV-116 in rats
25. Candesartan cilexetil: A review of its preclinical pharmacology
26. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion